ArticleRare tumors2026
Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report.
Article in Rare tumors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Responses to conventional treatments, like chemotherapy and targeted agents, are generally infrequent, and of brief duration in patients with metastatic soft tissue sarcomas. We present a case of metastatic myxoid liposarcoma that achieved biopsy-proven complete remission with minimal toxicity following the addition of pembrolizumab to pazopanib as fourth-line treatment. This regimen resulted in significant tumor regression following just five doses. After 15 doses of pembrolizumab, radiographs demonstrated an ongoing response, with stable residual lesions, and a biopsy of a sacral lesion confirmed a pathologic complete remission. The patient subsequently discontinued all therapies and remains in an ongoing unmaintained remission. The combination of pembrolizumab and pazopanib demonstrated unexpected clinical benefit with minimal toxicity, suggesting that it may be worthy of further investigation in myxoid liposarcoma and possibly other histologic subtypes of STS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.